ucsf-breast-coverage

This early study tests abemaciclib with pembrolizumab in selected advanced breast and lung cancers. It examines safety and treatment activity.

This study tests whether telephone counseling helps cancer survivors become more physically active. It also follows fitness, fatigue and mood.

This study evaluates an AI tool for breast cancer education. It checks the safety and accuracy of answers and how patients and clinicians experience the tool.

This study evaluates a portable scalp-cooling system during breast cancer chemotherapy. It asks how well the device limits hair loss.

This study tests ARX788, a drug attached to an antibody that binds HER2, in advanced breast cancer with low HER2 expression.

This expanded-access program provided at-home injections of pertuzumab and trastuzumab to support continuity of care during the pandemic. It is not a randomized trial; the registry now marks the program approved for marketing.

ATEMPT 2.0 compares a shorter course of T-DM1 followed by trastuzumab with paclitaxel and trastuzumab after breast surgery, tracking side effects and cancer recurrence.

This study tests avelumab with different drug combinations in advanced triple-negative breast cancer. Some groups receive treatment intended to stimulate the immune system before the main combination.

AVIATOR compares trastuzumab and vinorelbine with combinations that add avelumab, with or without utomilumab. It asks whether the added immune treatments improve control of advanced HER2-positive breast cancer.

This study compares bazedoxifene plus conjugated estrogens with a waiting-list group. It measures breast cancer risk markers and menopausal symptoms, rather than treating an existing breast cancer.

This study collects body composition measurements and compares them with breast reconstruction outcomes. It is an observational study, not a trial of cancer treatment.

This registry follows people receiving approved antibody-linked drugs as part of routine breast cancer care. It studies outcomes when these drugs are used in sequence without assigning the treatment.

This study examines whether bacteria in breast tissue are associated with infections after reconstruction. It also studies how an antibiotic changes the breast microbiome.

This study tests cediranib with olaparib in selected advanced cancers, including triple-negative breast cancer. It asks whether the combination can shrink tumors; it is not a study of treatment after curative breast surgery.

This early study tests CLSP-1025, which aims to bring immune cells to cancer cells displaying a particular mutated p53 fragment. Both the mutation and a matching immune-system marker are required.

CompassHER2 RD compares T-DM1 with or without tucatinib after surgery when cancer remains following pre-surgery therapy. It asks whether adding tucatinib lowers the chance of relapse.

CompassHER2-pCR tests whether people whose cancer clears with a shorter course of pre-surgery treatment can receive less chemotherapy afterward. Further treatment depends on what is found at surgery.

COUNTS 2.0 tests a virtual service that helps people navigate their care. It measures use, satisfaction and access to support.

RECAST tests whether hormone therapy and repeated scans can help identify people with ductal carcinoma in situ who can continue careful monitoring. Surgery is recommended if the study evaluations indicate it is needed.

This study compares denosumab with placebo to see whether it prevents breast cancer in women with an inherited BRCA1 mutation. It is a prevention study rather than treatment for diagnosed cancer.

This study compares usual chemotherapy with or without durvalumab in a selected high-risk group of early breast cancers. It asks whether adding immune treatment lowers the chance of a cancer-related event.

E5103 compares chemotherapy after breast surgery with or without bevacizumab. It measures whether adding the drug changes the chance of cancer recurrence.

This early study tests imlunestrant, originally called LY3484356, alone or with other cancer therapies. It studies safety and activity in advanced breast or endometrial cancer.

This study tests estradiol in triple-negative breast cancers that express a different estrogen receptor, ER beta. That selection differs from the usual ER-alpha test used to classify breast cancer.

FABREC compares shorter-course with conventional radiation after mastectomy and reconstruction. It measures patient-reported outcomes and effects on reconstruction and cancer control.

FEATURE studies whether PET/CT scans can measure treatment response in breast cancer that has spread mainly to bones. It evaluates imaging rather than assigning a new cancer treatment.

FLEX links breast tumor gene-expression tests with clinical outcomes. It is a registry for studying new patterns in the data, rather than assigning a new treatment.

This study tests radiation to the brain and spinal cord while reducing radiation to a brain region involved in memory. It examines cancer control and effects on brain function.

IACS3 compares a program of nutrition, lifestyle practices, yoga and therapeutic touch with a health education program. This pilot study focuses on feasibility and participation, not proof that either program prevents recurrence.

This study evaluates radiation delivered during breast surgery. It follows side effects and cancer outcomes to assess this approach.

LoTam compares low-dose tamoxifen with usual hormone therapy after early breast cancer. The registry currently marks the study suspended.

This early study tests LOXO-783 alone and with other cancer treatments in tumors with selected PIK3CA gene changes. It looks at safety, dose and early treatment activity.

This first human study tests MEN2312, a drug that blocks an enzyme involved in controlling gene activity. It studies safety, dose and early signs of activity in advanced breast cancer.

This study uses an AI risk assessment to select people for additional breast MRI screening. It measures cancer detection rather than testing treatment for an existing cancer.

This study evaluates using MRI to plan breast radiation treatment. It examines whether the scans can be incorporated into routine planning and improve it.

This early study injects NBTXR3 into tumors and activates it with radiation alongside immune treatment. It studies safety and early signs of activity.

This early study tests NX-1607 alone or with paclitaxel in selected advanced cancers. It seeks a tolerable dose and early evidence of treatment activity.

This study compares olaparib alone with olaparib plus atezolizumab in advanced BRCA-mutant breast cancer. It tests adding immune treatment to DNA-repair inhibition, rather than treatment after curative breast surgery.

This early study tests donor-derived immune cells engineered to recognize a tumor-associated protein. It evaluates dose and safety across selected advanced solid tumors.

This early study tests palazestrant with ribociclib, alpelisib, everolimus or atirmociclib. It seeks suitable combination doses and evaluates side effects and drug levels.

PLUMB follows people with metastatic lobular breast cancer and collects clinical data and samples. It aims to improve how treatment response is measured for this cancer subtype.

PROSPECTIVE uses MRI and other selection criteria to identify people who may omit radiation after breast surgery. It follows whether cancer returns in the same breast.

This study tests a procedure that uses brief electrical pulses to treat a tumor in people with metastatic breast cancer. It evaluates the procedure rather than a new drug.

This observational study follows symptoms and quality of life in people whose breast cancer has spread to the brain or its coverings. It examines how these experiences relate to care decisions.

QuantifyHER evaluates more precise ways to measure HER2 in tumors. It asks whether these measurements help distinguish people who respond to trastuzumab deruxtecan from those who do not.

This registry collects clinical information, blood and tumor samples from people with recurrent or metastatic breast cancer. It aims to understand tumor spread and differences in treatment response.

This early study tests RNDO-564 alone or with pembrolizumab in selected advanced tumors. It examines dose, side effects and early treatment activity.

This expanded-access record concerns selpercatinib for cancers with activating RET changes. The registry now marks the program approved for marketing; this does not mean the former access program is recruiting.

This study compares two ways to deliver support during cancer care: a technology-based approach and a redesigned care team. It studies care delivery rather than a new cancer drug.

S0221 compares schedules for chemotherapy after breast surgery. It studies which schedule controls cancer while tracking side effects.

S1207 compares hormone therapy with or without everolimus after breast cancer treatment. It asks whether adding everolimus changes the chance of recurrence.

SYNERGY-AI evaluates an AI-assisted service for matching people with cancer to clinical trials. It studies matching and enrollment, not the effectiveness of a particular cancer drug.

This study compares tamoxifen and letrozole during ovarian stimulation before cancer treatment. It asks which approach produces more mature eggs for fertility preservation.

This study compares usual care with text reminders and telephone counseling to support taking prescribed hormone therapy. It studies medication use rather than a new hormone drug.

This study tests combinations of tools to support healthier eating and physical activity after cancer treatment. It measures health behaviors and body weight.

TRADE DXd studies the order of two antibody-linked drugs, trastuzumab deruxtecan and datopotamab deruxtecan. It asks how well one works after the other stops controlling the cancer.

This early study combines trastuzumab deruxtecan with pembrolizumab in advanced breast or lung cancer. It studies a suitable dose, side effects and tumor response.

This study adds tucatinib after local treatment for cancer progression in the brain while continuing selected HER2-directed therapy. It follows further progression in people whose cancer outside the brain remains controlled.